(97) Real-World Prescription Pattern Among Patients with Inflammatory Bowel Disease in Taiwan: A Multi-Institutional Electronic Medical Records Database Analysis

Saturday, August 27, 2022

8:00 AM – 6:00 PM CEST

Location: Hall C

Publication Number: 771

Presenting Author(s)

Chon Hou Kou
– LinKou Chang Gung Memorial Hospital, City, Taoyuan, Taiwan

Co-Author(s)

KAICHENG CHANG
– Chang Gung Memorial Hospital, Linkou, Gui Shan Qu, Taiwan
Hui-Yu Chen
– LinKou Chang Gung Memorial Hospital, Taoyuan City, Taiwan

Background: The treatment guideline of inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's Disease (CD), had change during past five years. Biologic agents (i.e., infliximab and adalimumab) became available for IBD treatment. However, the real-world prescription pattern among those patients remained unavailable.

Objectives: The present study was aimed to analyze the prescription pattern among UC and CD patients.

Methods: A retrospective study was conducted by using a multi-institutional electronic medical records database in Taiwan. We included newly diagnosis UC and CD between 1 January 2018 to 31 December 2020, respectively and defined the first diagnosis date as index date. The patients with other autoimmune disease before one year of index date were further excluded. We followed patients from the index date to patients’ death, last clinical visit, loss of follow-up or December 31, 2021. We classified IBD treatment into two main class: (1) conventional treatment (e.g., steroid, 5- aminosalicylates [5-ASA]) and (2) advanced treatment (e.g., biologics).

Results: We included a total of 1370 UC patients (mean [range] age: 49.4 [36.2–61.4] years; male: 50.2%) and 354 CD patients (mean [range] age: 45.7 [29.8–61.8] years; male: 59.7%). Among UC patients, the proportion of advanced treatment in each yearly diagnosed patient was similar (8.8%, 9.6% and 9.8% in 2018, 2019 and 2020, respectively). Among CD patients, the proportion of advanced treatment in each yearly diagnosed patient was increased (27.8%, 40.7% and 44.4% in in 2018, 2019 and 2020, respectively).

Conclusions: Prescription pattern in Taiwanese patients with UC and CD were consistent with the clinical guidelines. Those patients put a substantial economic burden on government health care system. Future studies on cost-effectiveness analyses are suggested.